News | Pulmonary Embolism | October 18, 2019

Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates

Study finds readmitted patients twice as likely to die than patients on their first admission

Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates

Image courtesy of the American Heart Association


October 18, 2019 —­­ Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than nonsmokers, according to new research presented at the CHEST Annual Meeting 2019, Oct. 19-23 in New Orleans. The research will be presented by Kam Sing Ho, M.D., from Mount Sinai St. Luke’s and Mount Sinai West in New York City. 

Pulmonary emboli (PE), or blood clots in the lung, are common and are associated with 100,000 deaths annually. Risk factors include advanced age, surgery, trauma, prolonged immobility, cancer, pregnancy, estrogen therapy, congestive heart failure and defects in blood coagulation factors.

The researchers conducted a retrospective study using the AHRQ-HCUP Nationwide Readmission Database to study the role of smoking in hospital readmissions with a primary diagnosis of PE and a secondary diagnosis of tobacco dependence, also called active smoking.

“Active smokers have a higher hospital readmission rate (34.2 percent) for pulmonary embolism,” stated Ho. “We found that 11 percent of smokers and nearly 9 percent of nonsmokers with PE were readmitted to the hospital within 30 days. The most common cause (13 percent) for readmission was PE. Smoking was an independent predictor associated with higher readmission rate.”

The investigators found that readmitted patients were twice as likely to die than patients on their first admission (6.27 percent vs. 3.16 percent). Smoking was associated with readmission as were female gender, atrial fibrillation, in-hospital oxygen requirement, Medicare insurance and additional illnesses. Private insurance and higher income status were associated with fewer readmissions.

“Previous reports have shown that smoking cessation services are underutilized within the hospital,” commented Ho. “The National Readmission Database provides a platform to identify these correlations. This is an early study with promising results, which we are planning further refine with our own hospital database. In the future, we want to incorporate smoking cessation services for all adults hospitalized with pulmonary emboli.”

Michelle Cao, M.D., member of the American College of Chest Physicians Scientific Presentations and Awards Committee and clinical associate professor at Stanford University, California, addressed the importance of smoking cessation and the next step in implementation: “This study provides an opportunity to evaluate methods of implementing tobacco cessation, in light of possible increased risk of pulmonary embolism in smokers. One of the questions posed is how can we better utilize in- hospital smoking cessation programs as well as outpatient programs. Can this service be driven by primary care providers and/or pulmonologists? Successful smoking cessation programs would have major implications on morbidity, mortality as well as economic burden.”

For more information: www.chestmeeting.chestnet.org


Related Content

News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home June 12, 2024
Home
News | Cardiovascular Clinical Studies

June 6, 2024 —Cleveland Clinic researchers found higher amounts of the sugar alcohol xylitol are associated with ...

Home June 06, 2024
Home
Subscribe Now